Influence of tumor cell culture supernatants on macrophage functional polarization: In vitro models of macrophage-tumor environment interaction

Tumori

Volumn 97, Issue 5, 2011, Pages 647-654

  Caras, Iuliana ^a   Tucureanu, Catalin ^a   Lerescu, Lucian ^a   Pitica, Ramona ^a   Melinceanu, Laura ^b   Neagu, Stefan ^c   Salageanu, Aurora ^a  

^a CANTACUZINO INSTITUTE   (Romania)

^b Sf Maria Hospital   (Romania)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Cytokine pattern; M1 M2 polarization; Macrophages; TAMs, tumor progression; Tumor associated macrophages

Indexed keywords

CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL DIFFERENTIATION; CELL INTERACTION; CELL POLARITY; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE FUNCTION; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN SECRETION; SOLID TUMOR; SUPERNATANT; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

EID: 83055193666     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1177/030089161109700518     Document Type: Article

References (30)

1. Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G: Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol, 142: 481-489, 2005. (Pubitemid 41719844)
2. Solinas G, Germano G, Mantovani A, Allavena P: Tumor-associated- macrophages (TAM) asmajor players of the cancer-related inflammation. J Leukoc Biol, 86: 1065-1073, 2009.
3. Allavena P, Sica A, Garlanda C, Mantovani A: The Yin-Yang of tumor-associatedmacrophages in neoplastic progression and immune surveillance. Immunol Rev, 222: 155-161, 2008. (Pubitemid 351430369)
4. Sica A, Schioppa T, Mantovani A, Allavena P: Tumour-associated- macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anticancer therapy. Eur J Cancer, 42: 717-727, 2006.
5. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, De Baetselier P: Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology, 211: 487-501, 2006.
6. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol, 70: 325-330, 2009.
7. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A: Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev, 25: 315-322, 2006. (Pubitemid 44922352)
8. Qian B, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell, 141: 39-51, 2010.
9. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A: Macrophage polarization in tumour progression. Semin Cancer Biol, 18: 349-355, 2008.
10. Schmid MC, Varner JA: Myeloid cell trafficking and tumor angiogenesis. Cancer Lett, 250: 1-8, 2007. (Pubitemid 46483840)
11. Bacman D, Merkel S, Croner R, Papadopoulos T, Brueckl W, Dimmler A: TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta 1 expression in colon carcinoma: a retrospective study. BMC Cancer, 7: 156, 2007.
12. Shih JY, Yuan A, Chen JJ, Yang PC: Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol, 2: 101-106, 2006.
13. Forssell J, Öberg A, Henriksson ML, Stenling R, Jung A, Palmqvist R: High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res, 13: 1472-1479, 2007. (Pubitemid 46450437)
14. Hofmeister V, Schrama D, Becker JC: Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother, 57: 1-17, 2007.
15. Mantovani A: Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. Eur J Cancer, 40: 1660-1667, 2004.
16. Hallam S, Escorcio-Correia M, Soper R, Schultheiss A, Hagemann T: Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-κB. J Pathol, 219: 143-152, 2009.
17. Solinas G, Schiarea S, Liguori M, Fabbri M, Pesce S, Zammataro L, Pasqualini F, Nebuloni M, Chiabrando C, Mantovani A, Allavena P: Tumor-conditioned macrophages secrete migration-stimulating factor: a new marker for M2-polarization, influencing tumor cell motility. J Immunol, 185: 642-652, 2010.
18. Werno C, Menrad H, Weigert A, Dehne N, Goerdt S, Schledzewski K, Kzhyshkowska J, Brüne B: Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. Carcinogenesis, 31: 1863-1872, 2010.
19. Lerescu L, Tucureanu C, Cara I, Neagu S, Melinceanu L, S l geanu A: Primary cell culture of human adenocarcinomas-practical considerations. Roum Arch Microbiol Immunol, 67: 55-66, 2008.
20. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH: Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J Invest Dermatol, 129: 1016-1025, 2008.
21. Verreck FA, De Boer T, Langenberg DM, Hoeve MA, Kramer M, Vaisberg E, Kastelein R, Kolk A, de Waal-Malefyt R, Ottenhoff TH: Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco) bacteria. Proc Natl Acad Sci USA, 101: 4560-4565, 2004. (Pubitemid 38437450)
22. Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I: Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest, 88: 896-906, 2008.
23. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 23: 549-555, 2002. (Pubitemid 35223554)
24. Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS: Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res, 56: 45-50, 2007. (Pubitemid 46356230)
25. Kim S, Takahashi H, Lin W, Descargues P, Grivennikov S, Kim Y, Luo J, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature, 457: 102-106, 2009.
26. Herbeuval JP, Lelievre E, Lambert C, Dy M, Genin C: Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6. J Immunol, 172: 4630-4636, 2004. (Pubitemid 38375282)
27. Duluc D, Delneste Y, Tan F, Moles MP, Grimaud L, Lenoir J, Preisser L, Anegon I, Catala L, Ifrah N: Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells. Blood, 110: 4319-4330, 2007. (Pubitemid 351377797)
28. Biswas SK, Sica A, Lewis CE: Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol, 180: 2011-2017, 2008.
29. Mantovani A, Sica A, Locati M: New vistas on macrophage differentiation and activation. Eur J Immunol, 37: 14-16, 2007. (Pubitemid 46128780)
30. Hagemann T, Wilson J, Burke F, Kulbe H, Li NF, Plüddemann A, Charles K, Gordon S, Balkwill FR: Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol, 176: 5023-5032, 2006.